help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christian, R. C.
Right arrow Articles by Fitzpatrick, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christian, R. C.
Right arrow Articles by Fitzpatrick, L. A.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 6 2562-2568
Copyright © 2003 by The Endocrine Society

Prevalence and Predictors of Coronary Artery Calcification in Women with Polycystic Ovary Syndrome

Rose C. Christian, Daniel A. Dumesic, Thomas Behrenbeck, Ann L. Oberg, Patrick F. Sheedy, II and Lorraine A. Fitzpatrick

Division of Endocrinology, Metabolism, Diabetes, and Nutrition, Department of Internal Medicine; Department of Obstetrics and Gynecology (D.A.D.); Division of Cardiovascular Diseases, Department of Internal Medicine (T.B.); Department of Health Sciences Research (A.L.O.); and Department of Radiology (P.F.S.), Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905

Address all correspondence and requests for reprints to: Lorraine A. Fitzpatrick, M.D., Division of Endocrinology, Metabolism, Diabetes, and Nutrition, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, Minnesota 55905. E-mail: fitz{at}mayo.edu.

Polycystic ovary syndrome (PCOS), a common endocrine disorder of reproductive-aged women, is associated with multiple risk factors for coronary heart disease (CHD), such as diabetes mellitus, dyslipidemia, visceral obesity, and hypertension. However, premature coronary atherosclerosis has not been demonstrated in PCOS women. Electron beam computed tomography (EBCT) noninvasively measures coronary artery calcium (CAC), a marker for coronary atherosclerosis. We measured CAC by EBCT in 30- to 45-yr-old premenopausal PCOS women and compared the results to CAC in 1) recruited normal ovulatory volunteers matched for age and weight to the PCOS cohort, and 2) community-dwelling women of similar age in an extant coronary calcium database. Healthy, community-dwelling, ovulatory controls (n = 71) were matched by age and body mass index (BMI) to PCOS women (n = 36). Women with diabetes or known CHD were excluded. Subjects underwent EBCT scanning, oral glucose tolerance testing, and CHD risk factor assessment.

PCOS women had significantly higher levels of serum total and low density lipoprotein cholesterol and testosterone levels than matched controls. PCOS and control women were obese and had a greater mean BMI than community-dwelling women (33 kg/m2 for PCOS vs. 31 kg/m2 for control; P < 0.001). CAC was more prevalent in PCOS women (39%) than in matched controls (21%; odds ratio, 2.4; P = 0.05) or community-dwelling women (9.9%; odds ratio, 5.9; P < 0.001). BMI, waist circumference, and total and low density lipoprotein cholesterol levels predicted CAC prevalence after adjustment for BMI.

CAC is more prevalent in PCOS women than in obese or nonobese women of similar age. PCOS women are at increased risk for atherosclerosis and should be targeted for primary prevention of CHD.

Data from the ECAC study was supported in part by NIH Grant R01-HL-46292. Salary support for R.C. was from NIH NHLB Training Grant (5-T32-07111) and the Mayo Clinic Women’s Health Fellowship, supported by an unrestricted educational grant from Solvay Pharmaceuticals, Inc. This work was supported in part by a General Clinical Research Center grant from the NIH (MO1-RR-00585), NIH HLBI Research Grant R01-HL-51736-7, NIH NCRR Grant K24-RR-17593, and research funding from the Mayo Foundation.

Abbreviations: BMI, Body mass index; CAC, coronary artery calcium; CHD, coronary heart disease; CI, confidence interval; CV, coefficient(s) of variation; EBCT, electron beam computed tomography; ECAC, Epidemiology of Coronary Artery Calcification; F-G, Ferriman-Gallwey; HDL, high density lipoprotein; IGT, impaired glucose tolerance; LDL, low density lipoprotein; Ln, natural log; OR, odds ratio; PCOS, polycystic ovary syndrome.




This article has been cited by other articles:


Home page
 Hum ReprodHome page
M. Rizzo, K. Berneis, M. Hersberger, I. Pepe, G. Di Fede, G. B. Rini, G. A. Spinas, and E. Carmina
Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype
Hum. Reprod., September 1, 2009; 24(9): 2286 - 2292.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Aigner, N. Bachofner, K. Klein, C. De Geyter, F. Hohla, W. Patsch, and C. Datz
Retinol-Binding Protein 4 in Polycystic Ovary Syndrome--Association with Steroid Hormones and Response to Pioglitazone Treatment
J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1229 - 1235.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. McRobb, D. J. Handelsman, and A. K. Heather
Androgen-Induced Progression of Arterial Calcification in Apolipoprotein E-Null Mice Is Uncoupled from Plaque Growth and Lipid Levels
Endocrinology, February 1, 2009; 150(2): 841 - 848.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. M. Hoeger
Polycystic Ovary Syndrome, Inflammation, and Statins: Do We Have the Right Target?
J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 35 - 37.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Sathyapalan, E. S. Kilpatrick, A.-M. Coady, and S. L. Atkin
The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled Study
J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 103 - 108.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M.-A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang, and R. H. Eckel
The Metabolic Syndrome
Endocr. Rev., December 1, 2008; 29(7): 777 - 822.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. S. Guzick
Do Cardiovascular Risk Factors in Polycystic Ovarian Syndrome Result in More Cardiovascular Events?
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1170 - 1171.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. J. Shaw, C. N. Bairey Merz, R. Azziz, F. Z. Stanczyk, G. Sopko, G. D. Braunstein, S. F. Kelsey, K. E. Kip, R. M. Cooper-DeHoff, B. D. Johnson, et al.
Postmenopausal Women with a History of Irregular Menses and Elevated Androgen Measurements at High Risk for Worsening Cardiovascular Event-Free Survival: Results from the National Institutes of Health--National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1276 - 1284.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
N. Zhang, Y.-H. Shi, C.-F. Hao, H. F Gu, Y. Li, Y.-R. Zhao, L.-C. Wang, and Z.-J. Chen
Association of +45G15G(T/G) and +276(G/T) polymorphisms in the ADIPOQ gene with polycystic ovary syndrome among Han Chinese women
Eur. J. Endocrinol., February 1, 2008; 158(2): 255 - 260.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. E. Nestler
Metformin for the Treatment of the Polycystic Ovary Syndrome
N. Engl. J. Med., January 3, 2008; 358(1): 47 - 54.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Shroff, A. Kerchner, M. Maifeld, E. J. R. Van Beek, D. Jagasia, and A. Dokras
Young Obese Women with Polycystic Ovary Syndrome Have Evidence of Early Coronary Atherosclerosis
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4609 - 4614.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M. Luque-Ramirez, C. Mendieta-Azcona, F. Alvarez-Blasco, and H. F. Escobar-Morreale
Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome
Hum. Reprod., December 1, 2007; 22(12): 3197 - 3203.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
R. S. Legro
A 27-Year-Old Woman With a Diagnosis of Polycystic Ovary Syndrome
JAMA, February 7, 2007; 297(5): 509 - 519.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Berneis, M. Rizzo, V. Lazzaroni, F. Fruzzetti, and E. Carmina
Atherogenic Lipoprotein Phenotype and Low-Density Lipoproteins Size and Subclasses in Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 186 - 189.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M.-J. Chen, W.-S. Yang, J.-H. Yang, C. K. Hsiao, Y.-S. Yang, and H.-N. Ho
Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS
Hum. Reprod., September 1, 2006; 21(9): 2266 - 2271.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
A. P. V. Dantas and K. Sandberg
Does 2-Methoxyestradiol Represent the New and Improved Hormone Replacement Therapy for Atherosclerosis?
Circ. Res., August 4, 2006; 99(3): 234 - 237.
[Full Text] [PDF]

Home page
 J. Lipid Res.Home page
J. R. Crouse III
Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art
J. Lipid Res., August 1, 2006; 47(8): 1677 - 1699.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
E. Diamanti-Kandarakis, T. Paterakis, K. Alexandraki, C. Piperi, A. Aessopos, I. Katsikis, N. Katsilambros, G. Kreatsas, and D. Panidis
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin
Hum. Reprod., June 1, 2006; 21(6): 1426 - 1431.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. L. Setji, N. D. Holland, L. L. Sanders, K. C. Pereira, A. M. Diehl, and A. J. Brown
Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease in Young Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1741 - 1747.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Paradisi, A. Biaggi, R. Savone, F. Ianniello, C. Tomei, L. Caforio, and A. Caruso
Cardiovascular Risk Factors in Healthy Women with Previous Gestational Hypertension
J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1233 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. C. Lo, S. L. Feigenbaum, J. Yang, A. R. Pressman, J. V. Selby, and A. S. Go
Epidemiology and Adverse Cardiovascular Risk Profile of Diagnosed Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1357 - 1363.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Topcu, M. Caliskan, E. E. Ozcimen, D. Tok, A. Uckuyu, D. Erdogan, H. Gullu, A. Yildirir, H. Zeyneloglu, and H. Muderrisoglu
Do young women with polycystic ovary syndrome show early evidence of preclinical coronary artery disease?
Hum. Reprod., April 1, 2006; 21(4): 930 - 935.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Kravariti, K. K. Naka, S. N. Kalantaridou, N. Kazakos, C. S. Katsouras, A. Makrigiannakis, E. A. Paraskevaidis, G. P. Chrousos, A. Tsatsoulis, and L. K. Michalis
Predictors of Endothelial Dysfunction in Young Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5088 - 5095.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Meyer, B. P. McGrath, J. Cameron, D. Kotsopoulos, and H. J. Teede
Vascular Dysfunction and Metabolic Parameters in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4630 - 4635.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Second World Congress on the Insulin Resistance Syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy
Diabetes Care, July 1, 2005; 28(7): 1821 - 1830.
[Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the
Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome
Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
E. B. Kilicdag, T. Bagis, E. Tarim, E. Aslan, S. Erkanli, E. Simsek, B. Haydardedeoglu, and E. Kuscu
Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial
Hum. Reprod., June 1, 2005; 20(6): 1521 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
E Diamanti-Kandarakis, K Alexandraki, A Protogerou, C Piperi, C Papamichael, A Aessopos, J Lekakis, and M Mavrikakis
Metformin administration improves endothelial function in women with polycystic ovary syndrome
Eur. J. Endocrinol., May 1, 2005; 152(5): 749 - 756.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Vryonidou, A. Papatheodorou, A. Tavridou, T. Terzi, V. Loi, I.-A. Vatalas, N. Batakis, C. Phenekos, and A. Dionyssiou-Asteriou
Association of Hyperandrogenemic and Metabolic Phenotype with Carotid Intima-Media Thickness in Young Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2740 - 2746.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
J. Vrbikova and D. Cibula
Combined oral contraceptives in the treatment of polycystic ovary syndrome
Hum. Reprod. Update, May 1, 2005; 11(3): 277 - 291.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. A. Ehrmann
Polycystic Ovary Syndrome
N. Engl. J. Med., March 24, 2005; 352(12): 1223 - 1236.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. Xita, I. Georgiou, A. Chatzikyriakidou, M. Vounatsou, G.-P. Papassotiriou, I. Papassotiriou, and A. Tsatsoulis
Effect of Adiponectin Gene Polymorphisms on Circulating Adiponectin and Insulin Resistance Indexes in Women with Polycystic Ovary Syndrome
Clin. Chem., February 1, 2005; 51(2): 416 - 423.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Ibanez and F. d. Zegher
Flutamide-Metformin plus Ethinylestradiol-Drospirenone for Lipolysis and Antiatherogenesis in Young Women with Ovarian Hyperandrogenism: The Key Role of Metformin at the Start and after More than One Year of Therapy
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 39 - 43.
[Abstract] [Full Text] [PDF]

Home page
 JRSMHome page
T. J Wilkin and L. D Voss
Metabolic syndrome: maladaptation to a modern world
J R Soc Med, November 1, 2004; 97(11): 511 - 520.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. O. Talbott, J. V. Zborowski, J. R. Rager, M. Y. Boudreaux, D. A. Edmundowicz, and D. S. Guzick
Evidence for an Association between Metabolic Cardiovascular Syndrome and Coronary and Aortic Calcification among Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5454 - 5461.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Ibanez, C. Valls, S. Cabre, and F. de Zegher
Flutamide-Metformin Plus Ethinylestradiol-Drospirenone for Lipolysis and Antiatherogenesis in Young Women with Ovarian Hyperandrogenism: The Key Role of Early, Low-Dose Flutamide
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4716 - 4720.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. S. Guzick
Cardiovascular Risk in PCOS
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3694 - 3695.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Orio Jr., S. Palomba, L. Spinelli, T. Cascella, L. Tauchmanova, F. Zullo, G. Lombardi, and A. Colao
The Cardiovascular Risk of Young Women with Polycystic Ovary Syndrome: An Observational, Analytical, Prospective Case-Control Study
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3696 - 3701.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Brettenthaler, C. De Geyter, P. R. Huber, and U. Keller
Effect of the Insulin Sensitizer Pioglitazone on Insulin Resistance, Hyperandrogenism, and Ovulatory Dysfunction in Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3835 - 3840.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Taponen, H. Martikainen, M.-R. Jarvelin, U. Sovio, J. Laitinen, A. Pouta, A.-L. Hartikainen, M. I. McCarthy, S. Franks, M. Paldanius, et al.
Metabolic Cardiovascular Disease Risk Factors in Women with Self-Reported Symptoms of Oligomenorrhea and/or Hirsutism: Northern Finland Birth Cohort 1966 Study
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2114 - 2118.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Boulman, Y. Levy, R. Leiba, S. Shachar, R. Linn, O. Zinder, and Z. Blumenfeld
Increased C-Reactive Protein Levels in the Polycystic Ovary Syndrome: A Marker of Cardiovascular Disease
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2160 - 2165.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
D. J. Salmi, H. C. Zisser, and L. Jovanovic
Screening for and Treatment of Polycystic Ovary Syndrome in Teenagers
Experimental Biology and Medicine, May 1, 2004; 229(5): 369 - 377.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. F. Escobar-Morreale, J. I. Botella-Carretero, G. Villuendas, J. Sancho, and J. L. San Millan
Serum Interleukin-18 Concentrations Are Increased in the Polycystic Ovary Syndrome: Relationship to Insulin Resistance and to Obesity
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 806 - 811.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
M. T. Sheehan
Polycystic Ovarian Syndrome: Diagnosis and Management
Clin. Med. Res., February 1, 2004; 2(1): 13 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)
Hum. Reprod., January 1, 2004; 19(1): 41 - 47.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Elsenbruch, S. Hahn, D. Kowalsky, A. H. Offner, M. Schedlowski, K. Mann, and O. E. Janssen
Quality of Life, Psychosocial Well-Being, and Sexual Satisfaction in Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5801 - 5807.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
J. L. Sharpless
Polycystic Ovary Syndrome and the Metabolic Syndrome
Clin. Diabetes, October 1, 2003; 21(4): 154 - 161.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
The Endocrine Society Meeting: Topics in Insulin Sensitivity and Hypertension
Diabetes Care, September 1, 2003; 26(9): 2679 - 2688.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society